Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Apoptosis
    (1)
  • Autophagy
    (2)
  • Epigenetic Reader Domain
    (1)
  • Histone Methyltransferase
    (13)
  • Others
    (4)
Filter
Search Result
Results for "

ezh1

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    17
    TargetMol | Activity
Valemetostat
T13279L1809336-39-7
Valemetostat (DS-3201) is a first-in-class EZH1/2 dual inhibitor.
  • $96
In Stock
Size
QTY
Tazemetostat
T17881403254-99-8
Tazemetostat (EPZ6438) is a histone methyltransferase EZH2 inhibitor (IC50=11 nM) that is orally active, selective, and SAM-competitive. Tazemetostat exhibits antitumor activity and may be used for the treatment of epithelioid sarcoma follicular lymphoma.
  • $59
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
(S)-HH2853
T731152202678-05-3
(S)-HH2853 is a potent dual inhibitor of EZH1 and EZH2, inhibiting EZH2_Y641F with an IC50 of <100 nM.(S)-HH2853 has potential antitumor activity and can be used in the study of autoimmune diseases.
  • $333
In Stock
Size
QTY
Tazemetostat hydrobromide
T170021467052-75-0In house
Tazemetostat hydrobromide (E-7438 hydrobromide) is a potent and selective EZH2 inhibitor. Tazemetostat hydrobromide inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 (Ki: 2.5 nM). Tazemetostat hydrobromide also inhibits EZH1 (IC50: 392 nM).
  • $36
In Stock
Size
QTY
TargetMol | Inhibitor Sale
CPI-360
T68101802175-06-9In house
CPI-360 is a small molecule EZH2 inhibitor (IC50: 0.002 μM, EC50: 0.080 μM) that shows antitumor activity in an EZH200-dependent tumor xenograft model.
  • $76
In Stock
Size
QTY
UNC1999
T30571431612-23-5
UNC1999 is a orally bioavailable, effective and specific inhibitor of EZH2 (IC50=2 nM) and EZH1 (IC50=45).
  • $31
In Stock
Size
QTY
TargetMol | Citations Cited
EPZ005687
T19051396772-26-1
EPZ005687, a potent and selective inhibitor of EZH2.
  • $53
In Stock
Size
QTY
TargetMol | Citations Cited
EPZ011989
T24351598383-40-4
EPZ011989 is a effective, specific orally bioavailable EZH2 inhibitor with Ki < 3 nM for EZH2 Y646 and EZH2 wt; 15-fold selectivity over EZH1 and >3000-fold selectivity over other HMTase.
  • $35
In Stock
Size
QTY
TargetMol | Citations Cited
GSK343
T60591346704-33-3
GSK343, a specific and effective EZH2 inhibitor (IC50=4 nM), exhibits 60 fold specificity activity against EZH1, and >1000 fold specificity activity against other histone methyltransferases.
  • $54
In Stock
Size
QTY
TargetMol | Citations Cited
CPI-169 racemate
T68091450655-76-1
CPI-169 racemate (CPI 169) is a potent, and selective EZH2 inhibitor with IC50 of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively.
  • $51
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Tulmimetostat
T401992567686-02-4
Tulmimetostat (CPI-0209) is an orally active EZH1 EZH2 inhibitor with antitumor activity, utilized in the study of ovarian cancer and advanced solid tumors.
  • $30
In Stock
Size
QTY
Tazemetostat trihydrochloride
T152401403255-00-4
Tazemetostat trihydrochloride is a selective and orally available inhibitor of EZH2 (IC50: 4 nM for rat EZH2). It inhibits the activity of human PRC2-containing wild-type EZH2 (Ki: 2.5 nM). It inhibits EZH2 (IC50s: 11 and 16 nM in peptide assay and nucleo
  • Inquiry Price
Size
QTY
(R)-OR-S1
T235751809336-19-3
(R)-OR-S1 is a SAM-competitive, highly selective, orally bioavailable dual inhibitor of EZH1/2.
  • $1,520
6-8 weeks
Size
QTY
Valemetostat tosylate
T132791809336-93-3
Valemetostat tosylate is a dual inhibitor of EZH1/2 and used in the research of relapsed/refractory peripheral T-cell lymphoma.
  • $916
6-8 weeks
Size
QTY
EZH2-IN-3
T254001377997-28-8
EZH2-IN-3 is an inhibitor of EZH2 and EZH1 with selective impact on diffuse large B cell lymphoma cell growth.
  • $1,520
6-8 weeks
Size
QTY
EZH2-IN-14
T731341979157-17-9
EZH2-IN-14 is a selective inhibitor of EZH2 (Histone Methyltransferase) with an IC50 value of 12 nM, targeting the methyltransferase activity of EZH2 PRC2 and reducing H3K27me3 levels. It exhibits more than 200-fold selectivity for EZH2 over the closely related H3K27 methyltransferase, EZH1.
  • $1,970
8-10 weeks
Size
QTY
EPZ011989 HCl(1598383-40-4 Free base)
T2435L2095432-26-9
EPZ011989 is a highly potent and selective oral EZH2 inhibitor with Ki value <3 nM.
  • Inquiry Price
8-10 weeks
Size
QTY